Akademik Veri Yönetim Sistemi
AASLD THE LIVER MEETİNG DIGITAL EXPERIENCE, 12 - 15 Kasım 2021, cilt.74, ss.480-481, (Özet Bildiri)
EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE IN HEPATITIS B VIRUS-INFECTED PATIENTS WITH CHRONIC HEMODIALYSIS AND RENAL TRANSPLANTATION: A PRELIMINARY RESULTHaydar Adanir1, Digdem Ozer Etik2, Abdullah Emre Yildirim3, Shahin Mehdiyev4, Suna Yapali5, Arif Mansur Cosar6, Derya Ari7, Hale Gökcan8, Tufan Teker9, Murat Kiyici9, Yasemin Hatice Balaban10, Huseyin Alkim11, Enver Ucbilek12, Yasemin Ünsal13, Murat Harputluoglu14, Sezgin Vatansever15, Mehmet Demir16,17, Fatih Guzelbulut18, Feyza Gunduz4, Sedat Boyacioglu2, Yilmaz Bilgic14, Nergis Ekmen13, Mehmet Arslan6, Halis Şimşek10, Meral Akdogan7, Dinc Dincer1, Nurdan Tozun5 and Ramazan Idilman8, (1)Gastroenterology, Akdeniz University School of Medicine, (2)Gastroenterology, Başkent University School of Medicine, (3)Gastroenterology, Gaziantep University School of Medicine, (4)Gastroenterology, Marmara University School of Medicine, (5)Gastroenterology, Acıbadem University School of Medicine, (6)Gastroenterology, Karadeniz Technical University School of Medicine, (7)Gastroenterology, Ankara City Hospital, (8)Gastroenterology, Ankara University School of Medicine, (9)Gastroenterology, Uludag University, School of Medicine, (10)Gastroenterology, Hacettepe University School of Medicine, (11)Gastroenterology, Health Sciences University, Sisli Hamidiye Etfal Training and Research Hospital, (12)Gastroenterology, Mersin University School of Medicine, (13)Gastroenterology, Gazi University School of Medicine, (14)Gastroenterology, Inonu University School of Medicine, (15)Gastroenterology, Katip Celebi University, (16)Mustafa Kemal University, (17)Gastroenterology, Mustafa Kemal University School of Medicine, (18)Gastroenterology, Haydarpasa Numune HospitalBackground: There are very limited data regarding the efficacy and safety of tenofovir alafenamide fumarate (TAF) in hemodialysis patients and renal transplant recipients . The aims of the present study were to assess the efficacy and tolerability of TAF treatment in hepatitis B virus-infected patients with chronic hemodialysis and renal transplantation . Methods: This is a multicentric, prospective study. Between January 2019 and June 2021, HBV-infected patients with hemodialysis and renal transplantation from 17 tertiary centers EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE IN HEPATITIS B VIRUS-INFECTED PATIENTS WITH CHRONIC HEMODIALYSIS AND RENAL TRANSPLANTATION: A PRELIMINARY RESULTHaydar Adanir1, Digdem Ozer Etik2, Abdullah Emre Yildirim3, Shahin Mehdiyev4, Suna Yapali5, Arif Mansur Cosar6, Derya Ari7, Hale Gökcan8, Tufan Teker9, Murat Kiyici9, Yasemin Hatice Balaban10, Huseyin Alkim11, Enver Ucbilek12, Yasemin Ünsal13, Murat Harputluoglu14, Sezgin Vatansever15, Mehmet Demir16,17, Fatih Guzelbulut18, Feyza Gunduz4, Sedat Boyacioglu2, Yilmaz Bilgic14, Nergis Ekmen13, Mehmet Arslan6, Halis Şimşek10, Meral Akdogan7, Dinc Dincer1, Nurdan Tozun5 and Ramazan Idilman8, (1)Gastroenterology, Akdeniz University School of Medicine, (2)Gastroenterology, Başkent University School of Medicine, (3)Gastroenterology, Gaziantep University School of Medicine, (4)Gastroenterology, Marmara University School of Medicine, (5)Gastroenterology, Acıbadem University School of Medicine, (6)Gastroenterology, Karadeniz Technical University School of Medicine, (7)Gastroenterology, Ankara City Hospital, (8)Gastroenterology, Ankara University School of Medicine, (9)Gastroenterology, Uludag University, School of Medicine, (10)Gastroenterology, Hacettepe University School of Medicine, (11)Gastroenterology, Health Sciences University, Sisli Hamidiye Etfal Training and Research Hospital, (12)Gastroenterology, Mersin University School of Medicine, (13)Gastroenterology, Gazi University School of Medicine, (14)Gastroenterology, Inonu University School of Medicine, (15)Gastroenterology, Katip Celebi University, (16)Mustafa Kemal University, (17)Gastroenterology, Mustafa Kemal University School of Medicine, (18)Gastroenterology, Haydarpasa Numune HospitalBackground: There are very limited data regarding the efficacy and safety of tenofovir alafenamide fumarate (TAF) in hemodialysis patients and renal transplant recipients . The aims of the present study were to assess the efficacy and tolerability of TAF treatment in hepatitis B virus-infected patients with chronic hemodialysis and renal transplantation . Methods: This is a multicentric, prospective study. Between January 2019 and June 2021, HBV-infected patients with hemodialysis and renal transplantation from 17 tertiary centers EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE IN HEPATITIS B VIRUS-INFECTED PATIENTS WITH CHRONIC HEMODIALYSIS AND RENAL TRANSPLANTATION: A PRELIMINARY RESULTHaydar Adanir1, Digdem Ozer Etik2, Abdullah Emre Yildirim3, Shahin Mehdiyev4, Suna Yapali5, Arif Mansur Cosar6, Derya Ari7, Hale Gökcan8, Tufan Teker9, Murat Kiyici9, Yasemin Hatice Balaban10, Huseyin Alkim11, Enver Ucbilek12, Yasemin Ünsal13, Murat Harputluoglu14, Sezgin Vatansever15, Mehmet Demir16,17, Fatih Guzelbulut18, Feyza Gunduz4, Sedat Boyacioglu2, Yilmaz Bilgic14, Nergis Ekmen13, Mehmet Arslan6, Halis Şimşek10, Meral Akdogan7, Dinc Dincer1, Nurdan Tozun5 and Ramazan Idilman8, (1)Gastroenterology, Akdeniz University School of Medicine, (2)Gastroenterology, Başkent University School of Medicine, (3)Gastroenterology, Gaziantep University School of Medicine, (4)Gastroenterology, Marmara University School of Medicine, (5)Gastroenterology, Acıbadem University School of Medicine, (6)Gastroenterology, Karadeniz Technical University School of Medicine, (7)Gastroenterology, Ankara City Hospital, (8)Gastroenterology, Ankara University School of Medicine, (9)Gastroenterology, Uludag University, School of Medicine, (10)Gastroenterology, Hacettepe University School of Medicine, (11)Gastroenterology, Health Sciences University, Sisli Hamidiye Etfal Training and Research Hospital, (12)Gastroenterology, Mersin University School of Medicine, (13)Gastroenterology, Gazi University School of Medicine, (14)Gastroenterology, Inonu University School of Medicine, (15)Gastroenterology, Katip Celebi University, (16)Mustafa Kemal University, (17)Gastroenterology, Mustafa Kemal University School of Medicine, (18)Gastroenterology, Haydarpasa Numune HospitalBackground: There are very limited data regarding the efficacy and safety of tenofovir alafenamide fumarate (TAF) in hemodialysis patients and renal transplant recipients . The aims of the present study were to assess the efficacy and tolerability of TAF treatment in hepatitis B virus-infected patients with chronic hemodialysis and renal transplantation . Methods: This is a multicentric, prospective study. Between January 2019 and June 2021, HBV-infected patients with hemodialysis and renal transplantation from 17 tertiary centers
EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE IN HEPATITIS B
VIRUS-INFECTED PATIENTS WITH CHRONIC HEMODIALYSIS AND RENAL
TRANSPLANTATION: A PRELIMINARY RESULT
Background and Aims: There are very limited data regarding the efficacy and safety of
tenofovir alafenamide fumarate (TAF) in hemodialysis patients and renal transplant
recipients. The aims of the present study were to assess the efficacy and tolerability of TAF
treatment in hepatitis B virus-infected patients with chronic hemodialysis and renal
transplantation.
Methods: This is a multicentric, prospective study. Between January 2019 and June 2021,
HBV-infected patients with hemodialysis and renal transplantation from 17 tertiary centers of
Turkey were enrolled. TAF was administered at a dose of 25 mg/day. Mean follow-up period
for patients with hemodialysis and renal transplant recipients were 10.4±4.7 and 11.8±7.0
months, respectively.
Results: A total of 77 HBV-infected patients were included into analyses: 16 patients were on
hemodialysis and 61 patients had renal transplantation. The mean ages were 54.2±15.4 and
46.5±11.0 years, retrospectively. Male gender was predominant (63% vs 71%, respectively).
Thirty-one patients (12 hemodialysis patients and 19 renal transplant patients) received TAF
treatment as first-line therapy, while 46 patients had switched to TAF treatment. Durations of
TAF treatment were 11.8±7 and 10.4±4.7 months, respectively. In renal transplant recipients,
82% were on tacrolimus-based, 23% were on cyclosporin-based and 15% on everolimus-
based treatments.
Overall, virological and biochemical response in 25 treatment-naïve patients was 92% and
96% at 12 months, respectively. None of the patients experienced HBV reactivation after the
switch to TAF treatment. TAF treatment was well tolerated. No serious adverse events were
reported. Renal function tests and serum phosphorus levels did not significantly change from
the baseline to the end of the follow-up period.
In Conclusion: Based on the preliminary results of this study, TAF is effective and tolerable
in HBV-infected patients with hemodialysis and renal transplant recipients.